Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Shares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations.

Moderna Earnings Hit by Falling Covid Vaccine Sales. Stock Slides.

Moderna Inc. MRNA, -1.20% said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period. Revenue fell to $5.084 billion from $7.211 billion a year ago.

Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half

Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets Company will file for regulatory approval for mRNA-1345, Moderna's investigational RSV vaccine for older adults, in the first half of 2023. mRNA-1345 was recently granted FDA Breakthrough Therapy Designation mRNA-1010 Phase 3 flu vaccine interim efficacy analysis expected to be reviewed by an independent DSMB before the end of the first quarter mRNA-4157, Moderna's investigational personalized cancer vaccine in combination with Keytruda®, was granted Breakthrough Therapy Designation; full data set to be shared at upcoming medical oncology meeting and in peer reviewed publication Company R&D investments planned to increase to $4.5 billion in 2023 CAMBRIDGE, MA / ACCESSWIRE / February 23, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022.

Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

Moderna stock jumped late Wednesday after the FDA granted its Merck-partnered cancer vaccine a breakthrough designation. The post Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation appeared first on Investor's Business Daily.

Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation

Moderna Inc. MRNA, -1.20% and Merck Inc. MRK, +0.08% shares increased in after-hours trading Wednesday after the pharmaceutical companies announced that a cancer-vaccine candidate received the “breakthrough therapy” designation from the Food and Drug Administration. Moderna shares rose 4% and Merck shares increased about 1% in late trading.

Moderna stock pops after receiving cancer-vaccine candidate gets FDA breakthrough designation

Merck

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The FDA granted Breakthrough Therapy Designation based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial.

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela

Moderna announced a partnership with Life Edit Therapeutics to tackle “some of the most challenging genetic diseases” using its mRNA technology.

Moderna Hopes To Build On mRNA Tech Used In Its Covid Shots—By Targeting Genetic Diseases

Enphase Energy

Freeport-McMoRan

iShares S&P 500 Growth ETF

Nucor

ON Semiconductor

Quanta Services

Steel Dynamics

Communication Services Select Sector SPDR Fund

It's been three years since the Covid crash tanked the S&P 500. But there's been still plenty of ways to make money since.

9 Stocks Jumped 200% In 3 Years Since Covid Rocked The World

Moderna Inc. MRNA, -3.91% announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies. Moderna's stock edged up 0.4% in premarket trading.

Moderna to collaborate with Life Edit on gene editing therapies

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, NC / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit's suite of proprietary gene editing technologies, including base editing, with Moderna's mRNA platform to advance in vivo gene editing therapies against a select set of therapeutic targets.

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Moderna shares have what it takes to gain over time.

Where Will Moderna Be in 5 Years?

PayPal

These two "pandemic stocks" are still great investments.

2 Resilient Growth Stocks to Buy and Hold Forever

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently authorized for use in individuals 18 years of age and older in Canada Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4/5) in Phase 2/3 clinical trials CAMBRIDGE, MA / ACCESSWIRE / February 17, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) in children and adolescents 6 to 17 years of age. The authorizations are based on a 25 μg booster dose for children ages 6 to 11 years old and a 50 μg booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster.

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

Moderna Inc.'s stock slid 5% Friday after the COVID vaccine maker said a trial of a flu-vaccine candidate that uses the same technology as its COVID shot had mixed results and failed to meet one of its goals.

Moderna's stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID.

Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi. The post Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees appeared first on Investor's Business Daily.

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees

Moderna (NASDAQ: MRNA ) stock fell 5% overnight after receiving mixed results on a large-scale study of its seasonal flu vaccine. The vaccine uses the same messenger RNA technology as Moderna's Covid-19 vaccine but targets four strains of influenza simultaneously.

Why Is Moderna (MRNA) Stock Down 5% Today?

Moderna Therapeutics Inc (NASDAQ:MRNA) shares have fallen more than 5% in pre-market trading after the biotechnology company reported mixed results from a study of its experimental influenza (flu) vaccine mRNA-1010.   The Phase 3 randomized trial was designed to evaluate and safety and immunogenicity of mRNA-1010 in adults aged 18 and older in the Southern Hemisphere.

Moderna shares fall on mixed flu vaccine study results

The shot got a strong immune response, but wasn't shown to be more effective than other vaccines.

Moderna Stock Falls as Study of Flu Vaccine Has Mixed Results

Moderna Inc. shares dove more than 5% in after-hours trading Thursday, after the company announced that a study into a flu vaccine candidate failed to reach one of its goals.

Moderna stock falls 5% after flu vaccine study results

mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza B/Victoria- and B/Yamagata-lineage strains mRNA-1010 showed an acceptable safety and tolerability profile Separate parallel pivotal Phase 3 efficacy study has now accrued over 200 PCR-confirmed cases, almost all influenza A consistent with the burden of disease in older adults; an independent DSMB is expected to review the first interim analysis of efficacy by the end of 1Q mRNA-1010 is one of five influenza vaccine candidates being evaluated by Moderna CAMBRIDGE, MA / ACCESSWIRE / February 16, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010 (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults. The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mRNA-1010 in adults 18 years and older in the Southern Hemisphere.

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

Cirrus Logic

On a hilltop in your town live two people. Joseph has an income of $400,000 a year but little savings.

Moderna and Cirrus Logic Are Balance Sheet Powerhouses

American Tower

Booking Hlds

EOG Resources

Home Depot

Intuit

NVIDIA

Pioneer Natural Resources

Walmart

Companies with a strong earnings growth rate are usually on traders' radars. Thus, it is important to keep track of stocks that are due to announce their earnings report card.

The 10 Biggest Companies Reporting Earnings in the Fourth Week of February 2023

Moderna Inc. MRNA, +0.95% said Tuesday it will keep its COVID-19 vaccines available and free for all people in the U.S. after the public-health emergency ends. For uninsured or underinsured people, Moderna said it will provide the vaccine at no cost through its patient assistance program.

Moderna promises to keep COVID vaccine free

Sen. Bernie Sanders, chairman of the Senate health committee, confirmed in a statement that Moderna CEO Stéphane Bancel will testify on the company's plans to increase the price of its Covid vaccine.

Moderna CEO Stephane Bancel will testify before Senate next month on Covid vaccine price hike

Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?

News for Moderna Stock (MRNA)